SOFTOMOTIVE
13.12.2018 10:44:19 CET | Business Wire | Press release
Businesses are still struggling to understand where and how to start Robotic Process Automation (RPA). This was also a key finding of the first-of-a-kind global research by Softomotive into RPA for Growth Companies conducted by KS&R .
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213005261/en/
“Despite uncertainty about which are the best processes to start automating, conventional wisdom is still typically to start with a big bang approach with high upfront investments associated with software, hardware and consulting, which carries more project risk, is more rigid and is less innovative, “said Marios Stavropoulos, CEO and co-founder of Softomotive, “In whichever currency you work in, it simply does not add up any longer. This has led some of our customers to say that there must be a better way to RPA rather than doing the same old thing. It is a time for a People1st approach to managing process automation to drive the next productivity revolution”.
Softomotive’s People1st Approach to RPA means putting People before Robots. People or “Citizen Developers” have the knowledge, skills and understanding to consistently select and develop the best tasks and processes to automate. Only once these have been tested and proven should they be deployed enterprise-wide, in either attended (Bots interacting with humans) or unattended mode (Bots acting independently).
Marios continued “Our People1st approach to RPA, by giving everyone their own digital assistant, places the power firmly into the hands of the people that do the work. This means in a People1st world, everyone is a “Citizen Developer” because they know best what works and what does not. It should not be left to a centralized department like the Center of Excellence (COE) to make this happen.”
The key advantages of adopting a People1st approach to RPA are summarised below:
|
Rationale |
Current, broken approach |
"People 1st" Approach |
|||
| Upfront Investment | High | Low | |||
| Risk | High | Low | |||
| Development Method |
Hybrid |
Agile | |||
| Automation Discovery | Limited | Supercharged | |||
| People Engagement | Low | High | |||
| Scope | COE | Business-Wide |
Source: Softomotive
Marios explained “A brand new business model for managing process automation is required to address our People1st approach which splits into three distinct stages called the 3 I’s. First, is Innovate , then Incubate and finally Implement. Each of these have a number of steps making up a seven step blue print for introducing a People1st approach to RPA.”
Argyris Kaninis, the COO and co-founder of Softomotive added, “Softomotive is the only RPA vendor to offer a desktop version WinAutomation , as well as server-based unattended and attended automation solutions ProcessRobot . These two working together are uniquely qualified to support a People 1st Approach to RPA because the desktop version is easily installed on everyone’s computer to accelerate innovation in process automation from the bottom up”. He continued, “Once the best automations have been filtered, tested and prepared by the COE, they can be scaled as business as usual using our enterprise RPA platform. The transition from one to the other is made easy since both solutions share the same RPA engine.”
ENDS
About Softomotive
Softomotive is a leading worldwide providers of Robotic Process Automation solutions, trusted by more than 8,000 companies worldwide.
Softomotive provides the smoothest RPA journey by allowing you to start small, learn quickly and scale seamlessly. This helps to reduce overall project risk and avoids high up-front costs which can make achieving a positive ROI that much harder.
- WinAutomation is the world’s best desktop automation tool and provides a powerful, robust and easy to use Windows-based platform for building software robots.
- ProcessRobot is a leading enterprise RPA platform, including enterprise grade security and controls, with links to best-of-breed AI technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181213005261/en/
Contact:
Softomotive Bob Weare, Chief Marketing Officer press@softomotive.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom